Your institution may have access to this item. Find your institution then sign in to continue.
Title
Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Authors
Bansback, N J; Ara, R; Barkham, N; Brennan, A; Fraser, A D; Conway, P; Reynolds, A; Emery, P
Abstract
Tumour necrosis factor (TNF) has been shown to improve the outcomes in patients with psoriatic arthritis (PsA). We estimate the long-term impact on health status of prescribing the TNF antagonist etanercept, and evaluate the cost-effectiveness in a health economic model.